Melanoma and immunotherapy

Hematol Oncol Clin North Am. 2009 Jun;23(3):547-64, ix-x. doi: 10.1016/j.hoc.2009.03.009.

Abstract

About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Cancer Vaccines / therapeutic use
  • Clinical Trials as Topic / statistics & numerical data
  • Combined Modality Therapy
  • Cytokines / therapeutic use
  • Dendritic Cells / immunology
  • Dendritic Cells / transplantation
  • Genetic Therapy
  • Humans
  • Immunologic Factors / therapeutic use
  • Immunotherapy* / methods
  • Immunotherapy, Active
  • Immunotherapy, Adoptive
  • Lymphocyte Depletion
  • Melanoma / drug therapy
  • Melanoma / pathology
  • Melanoma / secondary*
  • Melanoma / therapy*
  • Neoplasm Staging
  • Prognosis
  • Randomized Controlled Trials as Topic / statistics & numerical data
  • Skin Neoplasms / therapy
  • Survival Analysis

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Cancer Vaccines
  • Cytokines
  • Immunologic Factors